-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
During diabetes, the structure and function of the surrounding nerves are often disturbed, leading to sensory motor neuropathy.
About half of people with diabetic peripheral neuropathy (DPN) experience symptoms of chronic neuropathic pain, including severe tingling/burning and pain, which further leads to anxiety, sleep disorders, and a decline in quality of life.
currently, the main treatments for painful DPN include drugs that affect synthydiophrine and serotonin re-intake, sodium channel blockers, and opioids, as well as tight blood sugar control.
, however, none of these methods can restore the painful DPN's sensational disorder.
recently, researchers reported pain-resistant dysfunction mediated by POMC in diabetic sensory neurons.
in diabetic mice induced by streptococcus, pomc prologers were inhibited due to an increase in NF-kB p50 sub-base binding, resulting in loss of the basic POMC level in the exoskeleton nerve.
also observed a decrease in POMC levels in peripheral nervous system tissue in diabetic patients.
the μ pathways mediated by POMC are further impaired by the degradation of lysosomes of the physictors (MOR) of the POMC.
important is that the neuropathological esopologic esopologic esophysiology in diabetic mice is saved after the expression of POMC and MOR through the virus in the sensory nerve section.
the study identified an anti-pain mechanism for sensory nerve joints, paving the way for potential treatment for neuropathic pain in diabetes.